- Neurocrine once again posted disappointing Ingrezza sales, and while the post-pandemic reopening should help, it likely won't be an immediate recovery.
- Management is advancing a broad pipeline of high-risk/high-reward candidates into Phase II studies for a range of movement and psychiatric disorders.
- Neurocrine shares still appear meaningfully undervalued, but management is targeting riskier, higher-potential opportunities and investors need to understand that risk profile.
For further details see:
Neurocrine Biosciences: Pandemic Pressures And Few Pipeline Catalysts Continue To Weigh On NBIX